Indian pharmaceutical company Cipla plans to issue non-convertible debentures or bonds through a public offering or a private placement to raise Rs20bn ($293.2m).
The company plans to simultaneously issue equity shares, American depository receipts (ADRs), global depository receipts (GDRs), foreign currency convertible bonds or other securities / financial instruments to raise another Rs20bn ($293.2m).
Japanese pharmaceutical company Takeda Pharmaceutical (Takeda) has agreed to issue bonds to raise $20bn in a private placement, which will be subscribed to by institutional investors.
The company will issue dollar-denominated straight bonds worth $15bn, and yen-denominated subordinate loans worth $4.5bn, as part of the transaction.
The subordinated debt will have an option to be converted into equity in the future.
Takeda plans to use the proceeds for financing its acquisition of Shire.
Cadila Healthcare (Cadila) plans to issue securities in one or more public offerings.
The company will issue equity shares, convertible bonds, and debentures through qualified institutional placement.
Based in India, Cadila is involved in the discovery, development, production and marketing of a wide range of healthcare products.
Healthcare company Helios-Huaming has secured funds in a Pre Series A funding round provided by investment holding company Suzhou Oriza Holdings.
Both companies involved in the transaction are based in China.
Irish pharmaceutical company Allergan has implemented an option to acquire Aptinyx Inc’s AGN-241751 drug candidate.
Allergan was granted rights to small molecules of Aptinyx, as part of a research collaboration signed in September 2015.
Based in the US, Aptinyx is biopharmaceutical company spun out from US-based biopharmaceutical company Naurex.
Allergan has also acquired rapastinel, an intravenously administered N-methyl-D-aspartate (NMDA) receptor modulating tetrapeptide, as part of the transaction.
Swedish life science company Enzymatica has signed a distribution agreement with Greece-based pharmaceutical company, Qualia Pharma.
Qualia Pharma will market Enzymatica’s ColdZyme mouth spray in the Greek and Cyprus markets, as part of the agreement.